North American angel investing 2026: dollars up 12%, but checks land on fewer companies

On 13 July 2026 the Angel Capital Association published its 2026 Angel Funders Report, built from data submitted by member angel groups across the United States and Canada. The headline figure is modest next to institutional venture capital: $491.3 million in 2025, up 12% from $437 million in 2024. But this is the earliest layer of the funding stack, so its structure matters more than its size.

The interesting part is not the 12%. ACA frames 2025 as the first sign of a disciplined recovery after several years of post-pandemic correction, characterised by angel groups deploying more capital per investment and per company. In other words, the money grew but the number of doors open to founders did not grow with it.

Bigger checks are a form of tightening

When an angel group keeps its annual budget flat but raises its average deal size, arithmetic dictates that fewer companies get funded. ACA records exactly that: capital per investment and per company both rose, which the association reads as greater selectivity and conviction. For founders this changes the access problem: a pre-seed round is no longer about convincing a few familiar names, but about assembling a wide enough syndicate with someone willing to lead and set terms.

Life sciences take nearly half the dollars; AI shows up in two-thirds of groups

Sector allocation is where angels diverge most from institutional venture. Per SSTI's reading of the report, 47% of angel dollars went to life sciences — at a time when global venture in 2026 is dominated by artificial intelligence. At the same time, ACA reports that nearly two in three angel groups made at least one AI investment. The two facts are not in conflict: AI appears in many portfolios but in small cheques, while life sciences absorbs most of the money because of its capital intensity.

SSTI also flags the attached risk: bringing a life-science product to market usually requires capital far beyond an angel's reach, so angel groups must line up deep-pocketed, specialised syndication partners. That is a test of an ecosystem's capital infrastructure, not just of individual appetite.

Exits: acquisition is the main door, median multiple 2.0x

The exit section deserves the closest reading. Per SSTI, M&A accounts for 85% of exits among angel-backed companies, secondaries for 12%, and the median exit multiple is 2.0x — above median venture distributions, though portfolio returns still depend on a handful of outsized winners.

• Dollars rose 12% but the number of funded companies did not follow — early-stage competition got harder, not easier.
• Nearly half of the money goes to life sciences, which demands a specialised co-investment network.
• 85% of exits are acquisitions; the exit plan should be designed from the first round.
• A 2.0x median multiple is a reminder that most deals return modestly.